找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Drug Resistance in Leukemia and Lymphoma III; G. J. L. Kaspers,R. Pieters,A. J. P. Veerman Book 1999 The Editor(s) (if applicable) and The

[复制链接]
查看: 31365|回复: 58
发表于 2025-3-21 19:19:15 | 显示全部楼层 |阅读模式
书目名称Drug Resistance in Leukemia and Lymphoma III
编辑G. J. L. Kaspers,R. Pieters,A. J. P. Veerman
视频video
丛书名称Advances in Experimental Medicine and Biology
图书封面Titlebook: Drug Resistance in Leukemia and Lymphoma III;  G. J. L. Kaspers,R. Pieters,A. J. P. Veerman Book 1999 The Editor(s) (if applicable) and The
描述Cellular drug resistance is a major limitation to the success of chemotherapy of leu­ kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am­ sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p­ glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in­ formation is provided on apoptosis and its regulators, and on the results of cell culture drug resista
出版日期Book 1999
关键词Antigen; apoptosis; chemotherapy; drug; drug resistance; imaging; interferon; leukemia; lymphoma; pathogenesi
版次1
doihttps://doi.org/10.1007/978-1-4615-4811-9
isbn_softcover978-1-4613-7180-9
isbn_ebook978-1-4615-4811-9Series ISSN 0065-2598 Series E-ISSN 2214-8019
issn_series 0065-2598
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Busines
The information of publication is updating

书目名称Drug Resistance in Leukemia and Lymphoma III影响因子(影响力)




书目名称Drug Resistance in Leukemia and Lymphoma III影响因子(影响力)学科排名




书目名称Drug Resistance in Leukemia and Lymphoma III网络公开度




书目名称Drug Resistance in Leukemia and Lymphoma III网络公开度学科排名




书目名称Drug Resistance in Leukemia and Lymphoma III被引频次




书目名称Drug Resistance in Leukemia and Lymphoma III被引频次学科排名




书目名称Drug Resistance in Leukemia and Lymphoma III年度引用




书目名称Drug Resistance in Leukemia and Lymphoma III年度引用学科排名




书目名称Drug Resistance in Leukemia and Lymphoma III读者反馈




书目名称Drug Resistance in Leukemia and Lymphoma III读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 22:06:00 | 显示全部楼层
https://doi.org/10.1007/978-3-7091-9414-0 strategies are being developed to circumvent drug resistance by inhibiting P-gp, prospective studies concerning the clinical relevance of P-gp in childhood leukemia are warranted. . P-gp was studied in 102 consecutive cases of de novo childhood ALL and in 34 relapsed patients. An immunocytochemical
发表于 2025-3-22 04:08:28 | 显示全部楼层
发表于 2025-3-22 08:16:31 | 显示全部楼层
https://doi.org/10.1007/978-3-642-83312-0Cyclosporin A (CsA), PSC833 and GF120918. We describe an investigation into the expression, using MRK16 and UIC2, and function of P-gp using daunorubicin with and without modulators by flow cytometric analysis on previously frozen blast cells from 27 patients with primary or secondary AML. We compar
发表于 2025-3-22 11:57:54 | 显示全部楼层
发表于 2025-3-22 15:39:35 | 显示全部楼层
发表于 2025-3-22 20:19:06 | 显示全部楼层
发表于 2025-3-22 21:14:08 | 显示全部楼层
发表于 2025-3-23 04:34:05 | 显示全部楼层
Väter, Männer und kindliche Entwicklungcellular mechanisms underlying this increased expression are completely unknown. Point mutations in the .1 promoter have been found in osteogenic sarcoma (Stein et al., Eur J of Cancer, 30A: 1541–1545, 1994). We therefore analyzed DNA from hematological malignancies for .1 promoter point mutations.
发表于 2025-3-23 06:15:30 | 显示全部楼层
https://doi.org/10.1007/978-3-322-85040-9ty can also be increased by combining the results of more than one assay. We have used a combination of flow cytometric assays to define MDR positive and negative blasts in 47 AML patients entered into MRC trials. Our primary test is a standardised and reproducible assay for anthracycline accumulati
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-24 08:30
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表